Pulse Biosciences Inc
PLSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.49B
Close$
$1.08
97.8% downside
Current Fair Value
97.8% downsideOvervalued by 97.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.49 Billion |
|---|---|
| Enterprise Value | $3.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.58 |
| Outstanding Shares | 69,200,020 |
Return
| Return on Equity | -80.46% |
|---|---|
| Return on Assets | -69.27% |
| Return on Invested Capital | -78.27% |
Valuation & Multiples
| P/E Ratio | -43.09 |
|---|---|
| PEG | -150.49 |
| Price to Sales | - |
| Price to Book Ratio | 49.13 |
| Enterprise Value to Revenue | 4532.32 |
| Enterprise Value to EBIT | -41.47 |
| Enterprise Value to Net Income | -43 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$625,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1802▼ 48.18% |
|---|---|
| Total Calls | 67,700▲ 138.38% |
| Total Puts | 12,200▼ 35.11% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.46%▲ 2.07% |
|---|---|
| Total Invested | $167.60M▲ 92.87% |
| Investors Holding | 98▲ 16.00% |
ESG Score
No data
About Pulse Biosciences Inc
95 employeesPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive ad...